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Introduction
SLE patients are at risk of tuberculosis (TB) infection
due to both secondary immunosuppression and intrin-
sic defects in innate immunity. On the other hand
infection can also perpetuate the development of an
autoimmunity [1,2].
Objectives
Here we report a case of pulmonary tuberculosis reacti-
vation in a SLE patient. The lupus activity was not
responsive to heavy immunosuppressants. It was only
controlled after commencement of anti TB treatment.
Methods
WLS was diagnosed SLE at the age of 16 with fever, rash,
oral ulcers, cytopenia, lupus nephritis (type II and III),
retinal vasculitis and positive anti dsDNA. She was started
on systemic steroid and Azathioprine. Symptoms became
better and steroid was gradually tapered. However
3 months later she developed relapse of lupus activity with
worsening lupus nephritis (active urinary sediments, heavy
proteinuria up to 7.6g/day), cytopenia and high anti
dsDNA titre. ESR was high but CRP was normal, a
pattern commonly seen in active lupus. Azathioprine
was switched to Mycophenolate Mofetil without much
success. CXR was performed which showed prominent
horizontal fissure of right lung. HRCT thorax scan, to
our surprise, showed features of early TB reactivation.
She had absolutely no respiratory symptom. Girl’s TST
and CXR before commencement of steroid were nega-
tive. Gamma Interferon Releasing Assay (IGRA) was
positive. Bronchoscopy finding was normal. Only the
BAL of the RUL bronchus grew Mycobacterium
Tuberculosis.
Upon further questioning the parents recalled that
the girl’s uncle died from pulmonary TB 4 years ago.
She stayed with his family during a summer holiday
8 years ago.
After commencing anti TB treatment, her SLE activity
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Table 1 Cumulative results
Items and reference value Before anti TB treatment, on Prednisolone,
Mycophenolate
After Anti TB treatment, on Prednisolone,
Mycophenolate
Hb d/dL 7.7 11.6
Wcc 10^9 2.7 5.3
C3 g/l (0.9-1.8) 0.21 0.98
C4 g/l (0.1-0.4) <0.02 0.2
Cr unol/l (49-83) 82 44
Albumin g/l (35-52) 23 39
24 hour urine total protein g/day
(<0.1)
7.6 0.3
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Conclusion
This case illustrated the need of considering TB infection
in endemic region as a cause for persistent SLE activity
despite treatment, even when the patient is “asympto-
matic” for TB. It is plausible the onset SLE in this patient
was actually triggered by the TB reactivation. This case
also argues whether in endemic area doing IGRA before
steroid commencement would have picked up the latent
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